DRUG
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
Status
Terminated
Phase
Phase 1 / Phase 2
Enrollment
16
Locations
1
Results
Posted
Publications
1
Study summary
What the protocol is testing.
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with Atherosclerotic Renal Artery Stenosis (ARAS), who are undergoing percutaneous transluminal angioplasty of the renal artery (PTRA).
Full detailed description
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with ARAS, who are undergoing percutaneous transluminal angioplasty of the renal artery (PTRA). The randomization (1:1 active:placebo) was stratified by a diagnosis of diabetes mellitus. Participants received either 0.05 mg/kg/h elamipretide or matching placebo, administered as an IV infusion at 60 mL/h infused 30 minutes before and continued 3 hours after PTRA of the renal artery. After completion of the PTRA and stenting, subjects were to receive standard treatment.
Interventions
Treatment arms and agents.
DRUG
Placebo
Timeline
From registration to results.
First posted
Dec 24, 2012
Study start
Dec 2012
Primary completion
Dec 2015
Study completion
May 2016
Results posted
Aug 11, 2020
Registry updated
Aug 11, 2020
Outcomes
What the study measures.
Primary outcomes
Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.
Time frame · Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..
Secondary outcomes
Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.
Time frame · Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.
Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA
Time frame · Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.
Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA
Time frame · Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys
Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.
Time frame · Baseline (Pre-PTRA) and 8 (+4) weeks post-PTRA
Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.
Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA
Time frame · Baseline (Pre-PTRA) , 27 hours post-PTRA and 8 weeks post-PTRA
Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.
Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA
Time frame · 27H post PTRA and 8 weeks Post PTRA
Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia
Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA
Time frame · Pre-PTRA and 27 hours post-PTRA and 8 weeks post-PTRA
Mean Change in Diastolic Blood Pressure
Time frame · Pre-PTRA, immediately post-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA
Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.
Eligibility
Who can take part.
- Minimum age
- 40 Years
- Maximum age
- 80 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * ≥40 and ≤80 years old. * Patients with hypertension (systolic blood pressure \[BP\] \>155 mm Hg) and/or requiring 2 or more antihypertensive medications: no restrictions will be placed on antihypertensive agents, although loop diuretics will be temporarily changed to diluting site agents (eg, hydrochlorothiazide, indapamide, metolazone) prior to each blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) study performed during the trial, unless, in the judgment of the Investigator, the change represents a hazard to the patient. ARAS patients will be identified based upon radiologic and clinical criteria suggestive of renovascular hypertension and/or hemodynamically significant renovascular disease \>60% lumen occlusion (determined by quantitative computed tomography angiography or Doppler ultrasound velocity \>200 cm/sec). * Have an estimated glomerular filtration rate of ≥15 ml/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) formula. * Have no contraindications to angiography such as severe contrast allergy. * Have no contraindications to non-contrast magnetic resonance evaluations such as a pacemaker or magnetically active metal fragments. * Able to comply with protocol. * Women of childbearing age must: * Have a negative pregnancy serum human chorionic gonadotropin test prior to receiving study drug. * Agree to use two forms of contraception for 3 months following receipt of the study drug. * Men who are sexually active and able to father a child, must agree to use one of the birth control methods listed below for the entire study and for at least 2 months after receiving the study drug: * Barrier methods (such as a condom or diaphragm) used with a spermicide. * Hormonal methods used by his partner, such as birth control pills, patches, injections, vaginal ring, or implants. * Intrauterine device (IUD) used by his partner. * Abstinence (no sex). * Competent and able to provide written informed consent Exclusion Criteria: * Advanced chronic kidney disease defined as either Stage 5 or end-stage renal disease requiring dialysis. * Have other clinically significant abnormalities or laboratory results that would, in the opinion of the investigators, compromise the safety of the patient including evidence of diabetic ketoacidosis, paraproteinemia, or triglycerides above 600 mg/dL. * Clinically significant medical conditions within the six months before administration of Bendavia (e.g., cancer, stroke, myocardial infarction, active angina, congestive heart failure) that would, in the opinion of the investigators, compromise the safety of the patient. * Have received an investigational drug within thirty (30) days of baseline. * Have a serum sodium \<135 mmol/L on the day of, and prior to, the PTRA. * Are pregnant or breast feeding.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Mayo Clinic
Rochester, Minnesota, United States
Related trials
More studies on Elamipretide.
NCT IDStudyPhase / statusEnrollmentUpdated
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Stealth BioTherapeutics Inc. · Barth Syndrome
Phase 4
Recruiting
48
2026-07
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc. · Age Related Macular Degeneration (ARMD)
Phase 3
Active, not recruiting
313
2026-05
FRDA Investigator Initiated Study (IIS) With Elamipretide
Children's Hospital of Philadelphia · Friedreich Ataxia
Phase 1 / Phase 2
Completed
20
2025-12
Study of Healthy Aging and Physical Function With Elamipretide
David Marcinek · Aging, Healthy
Phase 2
Recruiting
30
2025-12
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Stealth BioTherapeutics Inc. · Mitochondrial Myopathies · Mitochondrial Pathology
Phase 3
Completed
102
2025-10
An Intermediate Size Expanded Access Protocol of Elamipretide
Stealth BioTherapeutics Inc. · Mitochondrial Diseases · Barth Syndrome
Not applicable
Available
—
2025-02
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Stealth BioTherapeutics Inc. · Age-related Macular Degeneration
Phase 2
Completed
176
2024-07
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
Stealth BioTherapeutics Inc. · Barth Syndrome
Phase 2 / Phase 3
Completed
12
2024-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.